BPC-157

Compare vendor prices

Mechanism

BPC-157 is a synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV) corresponding to a partial fragment of a larger protein, "body protection compound," originally isolated from human gastric juice. It is sometimes called a pentadecapeptide, a reference to its 15-residue length. As sold, it is a laboratory-synthesized fragment.

The mechanisms proposed for BPC-157 come almost entirely from cell-culture and rodent studies. The most frequently cited are modulation of the nitric oxide (NO) signaling system, upregulation of vascular endothelial growth factor receptor 2 (VEGFR2, associated with the formation of new blood vessels, or angiogenesis) and activation of the FAK-paxillin pathway involved in cell migration. In laboratory injury models, these pathways have been linked to effects on gastrointestinal, tendon, ligament, and nerve tissue. FDA's 2026 review for its compounding advisory committee found that BPC-157's molecular targets have not been identified and that its mechanisms of action remain poorly understood. This is preclinical, largely animal-model evidence: BPC-157 has not completed the controlled human trials that would be needed to establish clinical effects in people.

Clinical and preclinical status

BPC-157 has been studied extensively in animals but has no completed Phase 3 registration trials in humans and is not approved by the FDA for any indication. The published literature is dominated by preclinical work, a large share of it from a single research group. Any description of BPC-157's activity therefore reflects laboratory findings rather than demonstrated clinical benefit.

For ulcerative colitis, the use it evaluated, FDA's 2026 review found one randomized, placebo-controlled trial, a Phase 2 study of a BPC-157 enema reported in 2005 only as a meeting abstract, and judged its data inadequate to support efficacy or safety. A 2015 Phase 1 safety and pharmacokinetics study registered by PharmaCotherapia (NCT02637284) has no posted results, and FDA's review found no associated publication. A University of Arkansas Phase 1 pilot after rotator cuff repair (NCT07803250), first posted in September 2026, was not yet recruiting in October 2026.

FDA and regulatory timeline

BPC-157's regulatory status in the United States has moved quickly, and the sequence is worth following:

• September 2023: The FDA placed BPC-157 in Category 2 of its interim 503A bulk drug substances list, the category for substances that "may present significant safety risks." The agency cited immunogenicity concerns for certain routes of administration, difficulty characterizing peptide-related impurities, and limited safety data. Category 2 status effectively barred licensed compounding pharmacies from preparing it.
• April 2026: The FDA announced on April 15, 2026 that it would remove BPC-157 from Category 2, effective seven days later, because both of its nominators had withdrawn their nominations. FDA's page now lists it among withdrawn nominations, with its safety text unchanged.
• July 2026: At its July 23-24, 2026 meeting, the Pharmacy Compounding Advisory Committee (PCAC) voted 8-6, with one abstention, to recommend adding both BPC-157 (free base) and BPC-157 acetate to the 503A bulks list. Both nominations had been withdrawn, and FDA evaluated the substance on its own initiative, for ulcerative colitis. FDA's own review staff had recommended against adding the substance, citing limited human data and difficulty characterizing the material. The committee voted against that recommendation.
• October 2026: HHS issued a policy under which it does not intend to take enforcement action against pharmacies and physicians compounding BPC-157 acetate in subcutaneous, intramuscular, oral or topical dosage forms, subject to ten conditions, until a final rule decides whether BPC-157 joins the 503A bulks list. Our post on the HHS policy covers its terms.

Three points matter when interpreting this timeline. First, an advisory committee recommendation is not a decision: PCAC votes are non-binding, the FDA would still need to add BPC-157 to the 503A list through formal notice-and-comment rulemaking before compounding pharmacies could legally prepare it. Second, even a favorable outcome would make BPC-157 a substance licensed pharmacies may compound against an individual patient's prescription, not an FDA-approved drug. FDA reviewed it for ulcerative colitis but has acknowledged that a listing may not be limited to a specific use. Third, none of this changes the status of research-grade BPC-157 sold by peptide vendors, which is offered strictly for laboratory research use only and not for human consumption.

Vendor naming conventions

BPC-157 is usually sold under its own name or close variants ("BPC 157," "BPC157"). A few aliases trace to its development history, such as PL-14736 and PL-10 (codes from early work by the pharmaceutical company Pliva) and the name "Bepecin." It is also frequently co-marketed with the peptide TB-500 in combination "healing" products such as the Wolverine Blend. PeptideScouter indexes BPC-157 vials per milligram (capsule, tablet, spray and dropper listings carry no per-milligram figure) and verifies identity against its molecular formula (C62H98N16O22, CAS 137525-51-0).

Frequently asked questions